Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;79(4):521-532.
doi: 10.1111/his.14378. Epub 2021 Aug 3.

Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma

Yuichiro Hamamoto  1   2 , Yoji Kukita  3 , Masanori Kitamura  1 , Masako Kurashige  2 , Hiroaki Masaie  4 , Shigeo Fuji  4 , Jun Ishikawa  4 , Keiichiro Honma  1 , Tomoko Wakasa  5 , Hitoshi Hanamoto  6 , Mitsuyoshi Hirokawa  7 , Ayana Suzuki  7 , Eiichi Morii  2 , Shin-Ichi Nakatsuka  8
Affiliations

Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma

Yuichiro Hamamoto et al. Histopathology. 2021 Oct.

Abstract

Aims: Follicular lymphoma (FL), comprising a minor subset of primary thyroid lymphomas, is divided into two groups based on Bcl-2 expression and IGH-BCL2 translocation. The clinicopathological features exhibited by Bcl-2-negative IGH-BCL2 translocation-negative FL of the thyroid (Bcl-2- /IGH-BCL2- tFL) are different from those of conventional FL; however, its lymphomagenesis remains unclear. Here, we collected samples from seven patients with Bcl-2- /IGH-BCL2- tFL to investigate their epigenetic and genetic aberrations.

Methods and results: The immunohistochemical profiles of epigenetic modifiers and the methylation status of histones were examined, including EZH2, MLL2/KMT2D, CBP/CREBBP, EP300, H3K27me3 and H3K4me3, in Bcl-2- /IGH-BCL2- tFL and Bcl-2-positive IGH-BCL2 translocation-positive FL of the thyroid (Bcl-2+ /IGH-BCL2+ tFL). Most Bcl-2- /IGH-BCL2- tFLs retained the positivity of epigenetic modifiers and lower expression of H3K27me3, although Bcl-2+ /IGH-BCL2+ tFLs exhibited aberrant immunohistochemical patterns of EZH2 and CBP/CREBBP and overexpression of H3K27me3. Samples from seven cases were further analysed using targeted sequencing, focusing on the exons of 409 key tumour suppressor genes and oncogenes. Bcl-2- /IGH-BCL2- tFLs do not have pathogenic mutations of epigenetic modifiers, such as EZH2, MLL2/KMT2D, MLL3/KMT2C, EP300 and ARID1A, which have been reported in FLs in the literature, whereas Bcl-2+ /IGH-BCL2+ tFLs are probably pathogenic/pathogenic missense mutations or frameshift mutations of these genes. Additionally, novel mutations in TET2 and EP400 were detected in Bcl-2- /IGH-BCL2- tFLs.

Conclusions: Different genetic and epigenetic abnormalities might be involved in the oncogenesis of Bcl-2- /IGH-BCL2- tFLs from Bcl-2+ /IGH-BCL2+ tFLs and other FLs.

Keywords: Bcl-2; epigenetics; follicular lymphoma; thyroid.

PubMed Disclaimer

References

    1. Noble VV, Ermann DA, Griffin EK, Silberstein PT. Primary thyroid lymphoma: an analysis of the National Cancer Database. Cureus 2019; 11; e4088.
    1. Hirokawa M, Suzuki A, Hashimoto Y et al. Prevalence and diagnostic challenges of thyroid lymphoma: a multi-institutional study in non-Western countries. Endocr. J. 2020; 67; 1085-1091.
    1. Bacon CM, Diss TC, Ye H et al. Follicular lymphoma of the thyroid gland. Am. J. Surg. Pathol. 2009; 33; 22-34.
    1. Korfi K, Ali S, Heward JA, Fitzgibbon J. Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations. Epigenetics 2017; 12; 370-377.
    1. van Dongen JJM, Langerak AW, Brüggemann M et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257-2317. https://doi.org/10.1038/sj.leu.2403202.

Substances

LinkOut - more resources